KRAS and lung carcinoma: In the ClinicalTrials.gov cohort NCT04185883, as reported at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer, the combination of sotorasib and RMC-4630 demonstrated a strong synergistic effect in treatment-naive patients harboring the KRAS G12C mutation.